Palvella Therapeutics, Inc.
PVLANASDAQHealthcareBiotechnology
As of Oct 26, 2026 close
- Market cap
- $1.81B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $68.96$161.38
- Volume (live)
- -
- Avg. volume (3M)
- 231.29K
Palvella Therapeutics (PVLA) Stock Price & Financial Analysis
Palvella Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $123.83 - $127.20 |
|---|---|
| 52-Week High | $161.38 |
| 52-Week Low | $68.96 |
| Open | $126.52 |
| Volume (last close) | 110.51K |
| Average Volume (3M) | 231.29K |
| 50-Day MA | $144.19 |
|---|---|
| 200-Day MA | $125.41 |
| 1-Year Change | +77.27% |
| Market Cap | 1.81B |
|---|---|
| Shares Outstanding | 14.36M |
| Price to Book (P/B) | 8.36 |
| EV/EBITDA | -26.54 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Palvella Therapeutics at a Glance
As of the Oct 26, 2026 close, Palvella Therapeutics (PVLA) has a market capitalization of $1.81B. Revenue fell 100.0% year over year.
As of its latest reported balance sheet, it holds $187.80M in cash and securities against $535.00K of debt, a net cash position of $187.27M.
Palvella Therapeutics does not currently pay a dividend.
The share price is up 77.3% over the past year. At $126.23 (the Oct 26, 2026 close) it sits within its 52-week range of $68.96 to $161.38, above its 200-day moving average of $125.41.
Based on 13 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $232.42, 84.1% above the Oct 26, 2026 close.
Frequently Asked Questions About Palvella Therapeutics
What is the current stock price for PVLA?
As of the Oct 26, 2026 close, PVLA stock trades at $126.23. The 52-week range is $68.96–$161.38, with a day range of $123.83–$127.20.
What is the P/E ratio for PVLA?
The P/E ratio (Price-to-Earnings) for PVLA is shown in the Key Statistics section. This valuation metric helps compare Palvella Therapeutics, Inc. to industry peers.
Does PVLA pay dividends?
Palvella Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for PVLA?
Based on ratings from 13 professional analysts over the last 90 days, the consensus for PVLA is Buy. The average 12-month price target is $232.42, a 84.1% upside from the Oct 26, 2026 close of $126.23.
What is the market cap of PVLA?
As of the Oct 26, 2026 close, Palvella Therapeutics's market capitalization is $1.81B, classifying it as a small-cap company. Palvella Therapeutics operates in the Healthcare sector within the Biotechnology industry.